According to the published report on current practice of hematopoietic SCT in Europe, high-dose therapy (HDT) with autologous stem cell support is a standard of care in paediatric patients with high risk (HR) or relapsed Ewing 0 s sarcoma (ES). Randomized trials, however, have not confirmed the value of this procedure yet. In this retrospective analysis we intended to evaluate the role of HDT as a consolidation therapy in first remission of ES. A total of 102 patients were included in the analysis and divided according to the following risk factors: metastatic disease at presentation, feasibility of surgery and histological response after induction. Forty-one patients were classified as standard risk (SR) patients, while the remaining 61 children, with at least one risk factor, were classified as HR patients. HR group patients were non-randomized and qualified according to the decision of the local clinician to give a conventional consolidation (CC) or to perform high-dose chemotherapy and radiotherapy in selected patients. Twenty-six children were given CC while 35 patients were treated with HDT. The HDT consisted of oral BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) followed by melphalan 140 mg/m 2 i.v. on day À 2. Probability of relapse-free survival (RFS) in median observation time was significantly worse in HR patients who were given CC therapy as compared with children with HR features receiving high-dose chemotherapy (0.27 vs 0.66 (P ¼ 0.008); OS 0.31 vs 0.71 (P ¼ 0.007), respectively). Patients from the SR group had a probability of RFS of 0.72 and OS of 0.75, and the difference between SR and HR patients after HDT was NS (P ¼ 0.37). Our observation confirms that the consolidation of the first-line treatment with BU and melphalan improves the outcome in ES patients with HR features.
INTRODUCTION
The optimal management of children and adolescents suffering from Ewing 0 s sarcoma (ES) is still not established. The long-term survival of patients is estimated to range from 63% for localized disease to 32% for metastatic ES. 1 Despite prospective trials, the optimal treatment needs to be determined. According to the published report on current practice of hematopoetic SCT in Europe, high-dose therapy (HDT) with autologous stem cell support is a standard of care in paediatric patients with high risk (HR) or relapsed ES. 2 Randomized trials, however, have not confirmed the value of this procedure yet. The international trial EURO-E.W.I.N.G. 99, conducted by six European National groups from Austria, Germany, France, The Netherlands, Switzerland and The United Kingdom, defined the following factors indicating prognosis of patients with ES: metastatic disease at presentation, site of metastases, the feasibility of local therapy, the histological response and initial tumour volume. According to these criteria, after receiving equal induction chemotherapy consisting of six courses with vincristin, ifosfamide, doxorubicin and etoposide (VIDE), patients with HR features (metastatic disease or those with localized and unresectable or large (4200 ml) tumour or poor histological responders (410% viable cells)) were eligible for randomization between conventional consolidation (CC) therapy with vincristin, actinomycin D and ifosfamide (VAI) or HDT with BU and melphalan (BuMel). The Polish Paediatric Solid Tumour Group did not participate in the EURO-E.W.I.N.G. 99 study, but the majority of the paediatric oncology centres followed the therapeutic guidelines of this programme. In this analysis we aimed to evaluate the role of HDT as a consolidation therapy in first remission of ES, based on 7 years 0 experience of five Polish paediatric oncology centres.
PATIENTS AND METHODS
A total of 119 patients diagnosed as having ES or primitive neuroectodermal tumour (PNET) and treated according to EURO-E.W.I.N.G. 99 were identified in five paediatric oncology centres between November 1999 and July 2006. The median age of the patients was 13.2 years (range 1 month to 19 years). There were 70 males and 49 females; 40 patients (33%) had a metastatic disease during diagnosis. In 65 (55%) patients primary tumour was located in the extremities, while in 54 (45%) patients the disease was located in the axial site. As we aimed to evaluate the role of HDT as a consolidation therapy in remission patients, we excluded from further analysis 12 children who developed progression of the disease during initial treatment with VIDE chemotherapy and/or surgery. Another five children were excluded because of the following reasons: four children received two or more cycles of induction chemotherapy different from 1 VIDE, and one boy, an 11-month-old infant, died of complications after the fifth cycle of induction chemotherapy with VIDE.
In all, 102 patients were included into the final analysis and divided according to the following risk factors: metastatic disease during diagnosis, feasibility of surgery and histological response after induction therapy (10 or more percent of viable cells were considered as having poor response). We were not able to collect sufficient data about tumour volume in our patients; therefore we did not consider this risk factor in our analysis. Fortyone patients were classified as standard risk (SR) patients while the remaining 61 children, with at least one risk factor, were classified as HR patients (HR). Twenty-nine children in the SR group received CC consisting of eight cycles of VAI and in 11 children who underwent 2 to 7 days of postoperative chemotherapy, ifosfamide was substituted with CY (VAC). Nine patients from the SR group received radiotherapy (RT), along with chemotherapy, for the tumour site and according to local physician reports the indications for RT were unknown histological response in seven and insufficient tissue margin after surgery in four patients.
HR group patients were non-randomized and qualified according to the decision of the local clinician to undertake CC, which included eight cycles of VAI or VAC, or high-dose chemotherapy and RT in selected patients. Twenty six children were given CC and 13 of them received additional RT, while 35 patients with HR features received HDT.
In total, 35 patients were treated with HDT for a median time from diagnosis to HDT of 273 days (range 149-493 days). Based on the data of higher efficacy of the BuMel regimen, as compared to the combination of CY, etoposide and melphalan, the BuMel regimen was selected by all Polish paediatric transplant centres in the therapy of 35 children qualifying for HDT. The status of the disease before HDT was reported by local investigators as CR in 24 and PR in 11 children. HDT consisted of oral BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) on days À 6, À 5, À 4 and À 3 followed by melphalan 140 mg/m 2 i.v. on day À 2. In three patients BU was substituted with treosulfan owing to clinical contraindication to BU therapy. The RT was administered in 10 patients in this group after HDT. Clinical details of the patients included in analysis are presented in Table 1 .
The stem cell source was PBSCs in 31 patients, BM in 2 patients and PBSC þ BM in 2 patients. Stem cells were infused on day 0 and the median number of CD34-positive cells infused was 3.75 Â 10 6 (ranging from 1.22 to 7.9 Â 10 6 ) per kg b.w. Supportive care was performed according to local guidelines of the institutions included in this analysis. The probabilities of relapse free survival (RFS) and OS were calculated by the Kaplan-Meier method; univariate analysis was performed by log-rank test and Cox model was used for multivariate analysis. Statistica 7.0 computer software was employed for data analysis and presentation of the results.
RESULTS
The median follow-up time of 102 patients included in the study was 54 months (range 18-127 months). The probability of RFS was 0.58 for the whole study group and OS was 0.62.
The probability of RFS in the median observation time was significantly worse in HR patients who were given CC therapy as compared to children with HR features receiving high-dose chemotherapy (0.27 vs 0.66 (P ¼ 0.008); OS 0.31 vs 0.71 (P ¼ 0.007), respectively). Patients from the SR group had a probability of RFS of 0.72 and OS of 0.75, and the difference between SR and HR patients after HDT was NS (P ¼ 0.37). The results of RFS and OS are presented in Figures 1 and 2 . The remission status was the most important factor influencing the outcome after HDT in HR patients; the difference in RFS between CR and PR status was 0.87 and 0.27 (P ¼ 0.0007). The OS, according to the remission status before HDT, was 0.92 vs 0.27 (P ¼ 0.0002) for CR and PR patients, respectively.
At present 63 (62%) patients from the study group are alive and 59 (58%) of them are in first CR of the disease. Four children (2 HR after HDT, 1 HR and 1 SR) are alive with diseases: relapse of ES (2) or second malignancy (2) . All children with progression during initial treatment (excluded from analysis) died of disease in a median time of 12 months (range 2-39 months). Out of four patients excluded because of different induction chemotherapy regimens, three are alive and disease free; all of them underwent BuMel HDT as a consolidation therapy.
Relapse occurred in 11/41 patients in the SR group (27%), 9/35 HR patients treated with HDT (26%) and 19/26 patients in the HR group who received CC (73%). The median time from diagnosis to relapse was 21 months (range 3-67 months). Two treatment-related deaths occurred in the HR group treated with HDT: one patient died of multiorgan failure 96 days post HDT and the second boy had intracranial bleeding 4 months post HDT. The second malignancy was recorded during a follow-up in three patients: two from the SR group (osteosarcoma 4.5 years and nonHodgkin's lymphoma 4 years post ES diagnosis) and one boy from the HR with CC group were diagnosed with secondary AML 1.5 years post first chemotherapy. Five patients received HDT with BuMel after relapse (three children from the SR group and two from the HR with CC group) and four of them subsequently relapsed and died of disease; one girl is still alive and disease free.
In the HR group we evaluated the following factors influencing RFS and OS: age below 14, primary tumour site, metastatic disease during diagnosis, feasibility of primary tumour surgery, histological response and HDT as a consolidation therapy. We found consolidation with HDT as the only significant factor for OS and RFS in patients with HR features (Table 2 ) In multivariate analysis we identified three factors significantly increasing the risk of relapse and death of analysed patients: CC (relative risk 3.6 and 2.7), age below 14 (relative risk 2.7 and 2.3) and no surgery of primary tumour (relative risk 1.7 and 2.1), respectively (Table 3) .
DISCUSSION
The results of the EURO-E.W.I.N.G. 99 trial published to date did not definitely confirm the value of high-dose chemotherapy in patients with ES. Results published for the last 15 years' retrospective analysis of efficacy of HDT in this group of patients are summarized in Table 4 .
A group of 18 patients with poor-risk ES, of whom 12 were in first CR, treated with BuMel consolidation was described by Atra et al. 3 The authors reported survival of 60% of the patients, but there were significant differences in previous therapies of these patients that could likely influence the results. Later, the favourable outcome in HR patients after high-dose chemotherapy was reported in first CR by a Spanish group; however, only 5 out of 20 transplanted patients had metastatic disease. 4 In the next report of 75 patients with metastatic disease, the authors concluded that BuMel consolidation could be beneficial for patients with lung-only or bone metastases. 5 The comparison of patients with ES treated in one institution with and without HDT suggested better results in transplanted children. 6 However, in this report, HDT regimen, consisting of melphalan, etoposide and CY, was used in a majority of patients and 6 out of 20 patients received HDT at the time of disease relapse.
The results of HDT published by Gardner et al. 7 suggested that the significant risk factors affecting relapse/progression of disease after SCT were recurrent and metastatic disease prior to HDT. In this study, of 117 patients, the authors also found that performance status before the procedure was important for the overall treatment outcome. In another study, a retrospective analysis of 47 HR ES children receiving HDT in a single institution showed long-term PFS in 56% of the patients. 8 A recent report described 281 patients with primary disseminated multifocal ES, for whom HDT was recommended. Owing to early progression and the local physician's and/or patient 0 s decision, this treatment was given to only 169 of those patients. Based on this study the authors developed a prognostic scoring model at diagnosis to be identified in the beginning for those patients who are at risk of treatment failure and are candidates for experimental therapies not involving HDT. 
Autologous transplantation K Drabko et al
The results published by Italian and Scandinavian groups reported a significantly better outcome after BuMel HDT than after conventional chemotherapy in HR patients, defined as poor histological responders. 10 Our observations are similar; however, our material histological response after induction chemotherapy was not a discriminating factor.
Two studies, by Rosenthal et al. 11 and Hawkins et al., 12 describe the attempts to perform two subsequent HDTs in poor prognosis or relapsed patients; 3-year survival in those patients, 38% and 45%, seems to be promising.
The dismal prognosis of recurrent or progressive ES according to a majority of the cited publications, as well as our results, is considered as an indication for experimental therapies. In patients with multifocal bone metastases, implementation of total body magnetic resonance imaging governing the compartment irradiation was reported to be more effective than high-dose chemotherapy alone. 13 A different approach of the new therapies was to utilize the graft versus tumour effect after allogeneic transplantation in relapsed patients; 14 however, the optimal intensity of conditioning regimen and optimal donor have not been determined yet. 15, 18 Other experimental therapies included immunotherapy with tumour-derived T-cells or dendritic cells 16 or monoclonal Abs against insulin-like growth factor type 1 receptor. 17 Our study collected the majority of children and adolescents with ES treated in Poland in similar conditions and resources, and for this reason our conclusions may be informative. Our results are based on retrospective analysis and may be influenced by several factors such as a lack of analysis of EWS/FLI fusion genes, which are known as an important factor determining prognosis in this type of tumour. 18 However, recent prospective studies from EURO-E.W.I.N.G. 99 and the COG group did not confirm this clinical significance. 19, 20 Patients with resistant disease are unlikely to proceed to HDT and in our analysis they were excluded to avoid the bias in favour of the HDT group. Our observation confirms that consolidation of the first-line treatment with BuMel improves the outcome in ES patients with HR features.
